Indoco Remedies Sustainability Profile
Indoco Remedies Ltd., a prominent player in the pharmaceutical industry, is headquartered in Mumbai, India. Established in 1945, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). With a strong presence in both domestic and international markets, Indoco Remedies operates in various regions, focusing on key therapeutic areas such as anti-infectives, cardiovascular, and central nervous system disorders. Renowned for its commitment to quality and innovation, Indoco Remedies has achieved several milestones, including regulatory approvals from major global health authorities. The company’s core offerings are distinguished by their adherence to stringent quality standards and a robust research and development framework. As a result, Indoco Remedies has established a solid market position, recognised for its reliability and excellence in the pharmaceutical sector.
DitchCarbon Score
How does Indoco Remedies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Indoco Remedies's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Indoco Remedies's reported carbon emissions
In 2024, Indoco Remedies reported total carbon emissions of approximately 15,000,000 kg CO2e for Scope 1 and about 36,500,000 kg CO2e for Scope 2, resulting in a combined total of around 52,500,000 kg CO2e. This marks a notable increase from 2023, where emissions were approximately 12,800,000 kg CO2e for Scope 1 and about 44,500,000 kg CO2e for Scope 2, totalling around 57,300,000 kg CO2e. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from owned or controlled sources and purchased electricity. Despite the increase in emissions, there are currently no specific reduction targets or climate pledges outlined by Indoco Remedies, which suggests a need for further commitment to climate action. Indoco Remedies operates within the pharmaceutical industry, where carbon emissions and sustainability are increasingly scrutinised. The absence of reduction initiatives or targets may impact their competitive positioning as stakeholders increasingly prioritise environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,827,330 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,543,700 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Indoco Remedies's Industry?
How Carbon Intensive is Indoco Remedies's Location?
Indoco Remedies's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Indoco Remedies has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
